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Abstract
Background: Most composite indices of disease activity and response criteria in RA have been
validated and compared in clinical trials rather than routine care. We therefore wanted to compare
the performance of the DAS28, SDAI and CDAI activity indices, their activity states, their response
criteria, and also compare with the ACR response criteria in an observational clinical setting.
Methods: Agreement between the criteria sets was investigated using κ statistics in a non-
randomized cohort of 1789 RA patients from southern Sweden, starting their first course of anti-
TNF-treatment. Mean disease duration was 12 years. Completer analysis was used.
Results: Agreement between high, moderate and low activity states was moderate or substantial,
with κ = 0.5 or better for all criteria. Agreement between SDAI and CDAI disease states was >
90% in these categories with κ > 0.8. DAS28 original and modified cut point remission had good
agreement (κ = 0.91). Agreement between responses was substantial at the overall/ACR20 level
(about 95%, κ = 0.7 or better) for all criteria. By contrast, agreement was poor between moderate
and high level responses.
Conclusion: Disease activity states according to the various indices perform similarly and show
substantial agreement at all levels except remission. Agreement between SDAI and CDAI states is
excellent. Response criteria, applied at the individual patient level, are hard to interpret and show
poor agreement, except at the lowest level of response. Thus, they should not be applied
uncritically in clinical practice.
Background
Indices of disease activity in RA, such as the Disease Activ-
ity Score in 28 Joints (DAS28) [1], the Simple Disease
Activity Index (SDAI) [2] and the Clinical Disease Activity
Index (CDAI) [3] and their respective cut-off levels for low
disease activity (LDA) and remission (no activity) are
tools that can be used in routine care. However, they have
been validated mainly in clinical trials, where patients are
meeting rigorous inclusion criteria and not always reflect
the "real world" situation [4].
Response to treatment in rheumatoid arthritis (RA), as
opposed to disease activity, denotes the improvement
between two time points due to some intervention. In the
Published: 23 April 2009
BMC Musculoskeletal Disorders 2009, 10:41 doi:10.1186/1471-2474-10-41
Received: 16 October 2008
Accepted: 23 April 2009
This article is available from: http://www.biomedcentral.com/1471-2474/10/41
© 2009 Gülfe et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2009, 10:41 http://www.biomedcentral.com/1471-2474/10/41trial setting, where the aim is to compare one treatment to
another (standard) or none at all (placebo), response is
the outcome measure of choice. The efficacy of a treat-
ment is expressed as the proportion of a patient group that
meets a certain response criterion. Indeed, disease activity
indices, their LDA and remission criteria are not recom-
mended as primary end points in trials due to low sensi-
tivity to change[5]. On the other hand, response criteria,
such as the DAS based EULAR moderate or good [6], SDAI
[2] and CDAI [3] minor or major, and American College
of Rheumatology (ACR) 20, 50 or 70% response [7], may
be less suitable in routine care. Unlike the group level,
individual responses will depend on the criteria set cho-
sen, at least at the stricter levels [8].
The cut-points for the various activity indexes and the
components of the response criteria are summarized in
Table 1.
The aim of the present study was to apply and compare
the performance of various activity indices and response
criteria in an observational cohort of patients from south-
ern Sweden with established RA, treated with their first
course of TNF-blockers. The findings may also serve as a
reference of what levels of activity and response are to be
expected in the "real life" setting without any formal or
financial restrictions. The comparisons will also serve as a
repository for future studies using one or the other meas-
ure as their primary end-point, relating them to results
observable with other primaries.
Methods
The South Swedish Arthritis Treatment Group (SSATG), a
network of hospital and office based rheumatologists in
southern Sweden, maintains a database into which all
courses of treatment with biologic drugs for RA and other
arthritides are entered as described elsewhere [9].
Patients eligible for the study had a diagnosis of RA, as
judged by the treating rheumatologist, and started their
first course of treatment with infliximab, etanercept, or
adalimumab from March 1999 through December 2006.
Due to the quality and safety monitoring character of the
register, no formal ethics committee approval was
required.
Patients were evaluated at baseline and 3 months. The fol-
low up protocol included tender and swollen 28 joint
counts, visual analogue scale (VAS) for pain and patient
global, evaluator global Likert scale, ESR, and CRP. Thus
DAS28, SDAI and CDAI could be calculated at each time
point as well as fulfilment of EULAR, ACR, SDAI and
CDAI response criteria at 3 months. The number of
patients falling into the different categories of disease
activity (including remission) when applying the cut off
levels proposed for DAS28 (original and modified), SDAI
and CDAI were then calculated.
Statistical methods
Descriptive statistics was used throughout. For each level
of disease activity and response, a reference criteria set was
chosen. Patients fulfilling and not fulfilling this com-
Table 1: Cut points for activity states according to various indexes (Panel A) and components of response criteria (Panel B)
A. Activity index
High Moderate Low Remission
DAS28 original# > 5,1 < 5,1 < 3,2 < 2,6
DAS28 modified cut off # > 5,5 < 5,5 < 3,6 < 2,4
SDAI## > 26 < 26 < 11 < 3,3
CDAI### > 22 < 22 < 10 < 2,8
B. Response criteria
TJC SJC Patient global VAS Patient pain VAS Evaluator global HAQ ESR CRP
ACR yes yes yes/no yes/no yes/no yes/no yes/no yes/no
EULAR yes yes yes no no no yes no
SDAI yes yes yes no yes no no yes
CDAI yes yes yes no yes no no no
# DAS28 = 0,56x√TJC28+0,28x√SJC28x0,7xlnESR+0,014xPat global VAS(in mm)
## SDAI=SJC+TJC+Pat global VAS(in cm)+Eval global VAS(in cm)+CRP(in mg/dL)
### CDAI = SJC+TJC+Pat global VAS(in cm)+Eval global VAS(in cm)
Cut points for activity states according to various indexes (Panel A) and components of response criteria (Panel B). Yes, required; no, not required; 
yes/no, in the ACR criteria, 3 of the variables marked "yes/no" are required (0 or 1 laboratory measure). TJC, tender joint count; SJC, swollen joint 
count; VAS, visual analogue scale; HAQ, health assessment questionnaire.Page 2 of 8
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applied to the same patients. The agreement, i e patients
fulfilling both sets (positive agreement) or neither (nega-
tive agreement) were then calculated as percentages and
assessed with κ statistics[10]. The procedure was then
repeated with a new reference criteria set. Thus, all com-
parisons were made between pairs of disease states and
according to different indices, but each comparison was
on the same level of disease activity. Likewise, pair wise
comparisons of response criteria fulfilment at each level
of response were performed. For example, DAS28 original
cut point low was compared to SDAI low, and ACR20 was
compared to EULAR overall response, etc. The κ values
indicate the level of agreement beyond chance between
two dichotomous variables. A frequently cited rule of
thumb [11] is that κ values > 0.8 correspond to almost
perfect agreement, 0.61–0.8 to substantial, 0.41–0.6 to
moderate and 0.2–0.4 to fair agreement. κ = 0 denotes
chance agreement. Completer analysis has been applied
due to the observational nature of the study.
Results
The eligibility criteria were met by 1789 patients. The
baseline characteristics for all patients, the 1258 with 3
month data and the 531 patients lacking data at 3 months
are given in Table 2. At baseline the majority (> 95%) of
patients were in high/intermediate disease activity irre-
spective of criteria sets used (Figure 1A). At 3 months, 12–
19% of patients had high, 39–46% had moderate, and
38–49% had low disease activity depending on criteria
set. According to DAS28 original and modified cut points,
23 and 19%, respectively, were in remission, whereas
about 8% were in remission according to SDAI and CDAI
(Figure 1B).
The agreement between each defined disease state at base-
line and 3 months, e.g. DAS28 low original cut point,
DAS28 low modified cut point, SDAI low and CDAI low,
are given in Table 3, along with their respective κ values.
In general, agreement between the activity states deter-
mined by the cut-points of the various activity indices was
moderate or substantial with κ values of about 0.5 or
higher. At 3 months, remission according to the 2 DAS28-
based categories had excellent agreement, κ = 0.84, and so
did SDAI and CDAI, κ = 0.91, whereas agreement between
DAS28-based agreement criteria and SDAI/CDAI was
moderate, κ = 0.40–0.47. SDAI and CDAI had excellent
agreement at all levels of disease activity (Table 3).
For the calculation of response at 3 months, 1258 patients
had complete data, with baseline characteristics similar to
the total cohort, but also to those with missing 3 month
data (table 2). Response rates were 60–70% at the ACR20/
overall level, 42% for EULAR original moderate, 19% for
EULAR modified moderate, 25% for SDAI and CDAI
minor response. At the major/good level, 35% responded
according to EULAR original and ACR50 and 50–55%
according to EULAR modified, SDAI and CDAI. Fourteen
per cent were ACR70 responders (Figure 2).
The responder agreements at 3 months are summarized in
Table 4. Substantial agreement (κ = 0.54–0.91) was found
at the modest response level of ACR20, EULAR overall,
SDAI overall and CDAI overall. Agreement at good/major
level between EULAR original on one hand and, ACR70,
SDAI, or CDAI on the other was poor (κ = 0.17–0.27),
whereas EULAR modified was in much better agreement
with SDAI and CDAI, κ = 0.69. SDAI and CDAI showed
good agreement with κ values between 0.68 and 0.91 at
the different response levels, while the agreement between
other criteria sets at different response levels was more
variable.
Discussion
The major findings in this observational study of a non-
randomized cohort of established RA patients, receiving
their first course of anti-TNF treatment and followed for 3
months, were that the disease activity states according to
the various indices performed similarly and showed mod-
erate or substantial agreement at all levels except remis-
sion. SDAI and CDAI stages show excellent agreement.
Agreement of response criteria is substantial at low
Table 2: Baseline characteristics of all included and those with and without 3 month data
All included N = 1789 With 3 month data N = 1258 Missing at 3 months N = 531
Mean Std dev Mean Std dev Mean Std dev
Percent female 77.2 77.8 77.8
Age 55.9 13.4 55.6 13.2 56.3 13.7
Disease duration, years 12.1 10.2 12.0 10.0 12.2 10.6
Ongoing DMARDs 0.85 0.57 0.85 0.57 0.84 0.57
DAS28 (0–10) 5.54 1.18 5.58 1.16 5.43 1.21
CDAI 30.6 12.3 31.0 12.1 32.2 13.9
HAQ (0–3) 1.34 0.64 1.36 0.64 1.29 0.62
CRP (mg/L) 30.8 33.0 31.4 33.6 28.9 31.3Page 3 of 8
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Disease stages at A) baseline and B) at 3 month follow up according to the different criteria setsFigure 1
Disease stages at A) baseline and B) at 3 month follow up according to the different criteria sets. Notice that 
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CDAI overall. At the moderate/minor level, when consid-
ered separately, agreement is poor, and this also holds
true for the good/major level.
The κ value tells to which extent agreement is not
explained by chance. The positive/negative agreements
give, however, an idea of the degree of agreement; the
closer total agreement (positive + negative) is to 100%,
the higher degree of agreement. Furthermore, κ depends
on sample size, and it is hard to interpret, if the compared
groups are small. This is illustated by the limited κ agree-
ment regarding both ACR70 responders and those reach-
ing remission.
Completer analysis may lead to bias, if the drop-outs at 3
months substantially differ from the completers. The
baseline data of the drop-outs and patients with 3 month
data was therefore examined separately and not found to
differ from the whole cohort in any clinically relevant way
(Table 2). Also, in the observational setting, only patients
remaining on therapy are contributing their data as time
Table 3: Agreement between disease activity states at baseline and three month according to various indices, expressed as 
percentages and κ values.
Baseline
Valid N DAS28 modified cut off SDAI CDAI
1657 1657 1681
Reference criterion Valid N % κ % κ % κ
High disease activity
DAS28 original 1657 52/35 0,73 60/27 0,69 61/24 0,65
DAS28 modified cut off 1657 50/31 0,62 51/27 0,54
SDAI 1672 67/26 0,83
Moderate disease activity
DAS28 original 1657 29/55 0,66 23/61 0,63 20/62 0,58
DAS28 modified cut off 1657 25/52 0,52 21/53 0,42
SDAI 1672 24/69 0,80
Low disease activity
DAS28 original 1657 2.7/94 0,64 1.3/96 0,55 1.3/96 0,54
DAS28 modified cut off 1657 1.8/94 0,46 1.6/94 0,41
SDAI 1672 1.7/97 0,81
Remission
DAS28 original 1657 0.6/99 0,91 0.1/99 0,15 0.1/99 0,15
DAS28 modified cut off 1657 0.1/99 0,18 0.1/99 0,18
SDAI 1672 0/100 1,00
3 month
Valid N 1214 1224 1232
High disease activity
DAS28 original 1206 12/83 0,82 13/79 0,72 13/78 0.69
DAS28 modified cut off 1214 11/82 0,72 11/80 0.67
SDAI 1224 15/80 0,83
Moderate disease activity
DAS28 original 1206 34/50 0,67 32/46 0,55 30/45 0,49
DAS28 modified cut off 1214 29/50 0,56 26/49 0,47
SDAI 1224 35/55 0,79
Low disease activity
DAS28 original 1206 38/51 0,77 33/53 0,71 32/52 0,67
DAS28 modified cut off 1214 39/47 0,71 37/46 0,66
SDAI 1224 40/55 0,88
Remission
DAS28 original 1206 18/77 0,87 7.7/77 0,42 7.3/76 0,40
DAS28 modified cut off 1214 7.1/80 0,47 6.7/80 0,44
SDAI 1224 7.5/91 0,91
Percentages denote positive agreement/negative agreement, i.e. per cent patients achieving both compared activity states/per cent patients 
achieving neither.Page 5 of 8
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Response at 3 months according to different criteria setsFigure 2
Response at 3 months according to different criteria sets. Notice that all ACR70 responders are include in the ACR50 
responders, and all ACR50 responders are included in the ACR20 responders. Similarly EULARoverall responders include 


















Table 4: Agreement of response according to various criteria sets at 3 months, expressed as percentages and κ values
Reference criterion
EULAR EULAR modified cut off SDAI CDAI
Valid N 1163 1163 1184 1195
Valid N % κ % κ % κ % κ
Overall response good+moderate good+moderate major+minor major+minor
ACR20 1234 61/22 0,61 59/24 0,62 62/19 0,54 61/19 0,54
EULAR 1163 71/23 0,83 73/17 0,71 72/17 0,68
EULAR modified cut off 1163 70/18 0,70 69/18 0,67
SDAI 1184 78/19 0,91
Moderate/minor response moderate moderate minor minor
ACR50 1234 13/33 0,00 3.5/47 0,00 7.3/41 0,00 5.6/45 0,00
EULAR 1163 14/54 0,27 13/43 0,04 10/46 0,03
EULAR modified cut off 1163 11/65 0,31 8.7/68 0,28
SDAI 1184 20/70 0,74
Good/major response good good major major
ACR70 1234 12/64 0,40 13/46 0,22 12/46 0,19 12/42 0,17
EULAR 1163 31/43 0,49 25/38 0,27 26/36 0,27
EULAR modified cut off 1163 45/39 0,69 47/37 0,69
SDAI 1184 51/42 0,86
Percentages denote positive agreement/negative agreement, i.e. per cent patients fulfilling both compared response criteria/per cent patients 
fulfilling neither.
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mation at 3 month follow up in our setting is higher than
in the British Biologics register [12]. There may be several
explanations for this, but the mandatory response
demanded for drug continuation in the British setting
may be one important factor. Also, the patients in the Brit-
ish register differ on numerous baseline characteristics
such as higher disease activity and very high disability
measured by the HAQ, all factors that may influence
response rates and future disease states [12,13]. Thus each
setting has its features and face to face comparison should
always be done with great care.
The distribution between disease state categories at base-
line and after 3 months is what may be expected in RA
patients with mean disease duration of 12 years and who
failed at least 2 different DMARDs. Achieving remission
and even low disease activity thus appears not to be a too
common event in established RA, treated with TNF-block-
ers. This is in agreement with other observational studies
[16]. In our setting with many long-standing cases, erosive
disease may preclude reaching remission in many patients
although inflammation per se is suppressed by treatment.
The small number of patients in low disease activity
(LDA) at baseline is explained by patients taking high
doses of prednisolone, also an accepted indication for
commencing TNF-blocker treatment according to the
Swedish guidelines.
The agreement between disease states, as defined by the
DAS28 original and modified cut points, SDAI and CDAI
proposed cut points, seems to be substantial. This is in
agreement with comparisons based on trial data [14]. The
excellent agreement of the disease state groups based on
SDAI and CDAI irrespective of activity level may be
accounted for by their great similarity: they contain the
same components, added together, except for the CRP
that is excluded from the CDAI. Our data thus support the
notion of acute phase reactant values contributing little to
the overall disease activity estimate [3]. The SDAI and
CDAI remission is achieved in fewer patients than the
DAS28 remission that appears less strict in this cohort, in
agreement with previous findings [15]. At the remission
level, agreement is almost perfect between EULAR original
and modified cut off, and also between SDAI and CDAI at
3 months, as may be expected (Table 3). The moderate
agreement between the DAS28-based and SDAI/CDAI
remission, may partly be accounted for by the greater
strictness of the latter (Figure 1B). Due to low patient
numbers reaching remission, κ must be interpreted with
caution in this category.
Response criteria are intended for clinical trials, and it is
thus not surprising that they perform poorly when
applied to individual RA patients in clinical practice.
Agreement (Table 3) is variable across criteria and
response levels with a tendency to be better at the less
strict overall level, where EULAR moderate and good are
merged to one group, as are SDAI and CDAI minor and
major responders. In this manner, substantial agreement
is achieved with ACR20, which includes all ACR50 and 70
responders, in accordance with previous findings [5,8].
The very poor κ values (often close to 0) for moderate
response comparisons seem to indicate random agree-
ment at the individual level. This may in part be due to the
construction of the criteria. Thus, the ACR50 responders
include all the ACR70 responders, whereas the EULAR
moderate category does not include the EULAR good. The
same mechanism may be operative concerning SDAI and
CDAI minor and major responders. EULAR response
according to original and modified definitions also
exhibit poor agreement, especially at the moderate level.
This is an expected finding, given the different cut-points
of DAS28 used in each case. The value of response criteria
in monitoring patients in routine care thus seems to be
limited. In contrast, group level responses in a clinical set-
ting can give some indication of the value of a particular
treatment in routine care. As far as the management of
individual RA patients with established disease is con-
cerned, at least in our setting, the achievement of an abso-
lute degree of disease activity seems to be a more relevant
treatment goal than fulfilling a response criterion, i.e.
achieving a given degree of improvement[8]. Our data
thus do not support the use of response criteria as aid in
the monitoring of RA-patients treated routinely with TNF-
blockers, but this should be verified in other clinical
cohorts.
In the development and evaluation of new treatment
modalities, as well as in routine care, a unified concept of
disease activity measurement and treatment aims will be
beneficial. The widespread use of reproducible and simple
composite measures of RA activity will facilitate this
development. The present study provides support for this,
but further validation of the indices in other cohorts is
desirable.
Conclusion
Disease activity states according to the various indices per-
form similarly and show substantial agreement at all lev-
els except remission. Agreement between SDAI and CDAI
states is excellent. Response criteria, applied at the indi-
vidual patient level, are hard to interpret and show poor
agreement, except at the lowest level of response. Thus,
they should not be applied uncritically in clinical practice.
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